BRPI0407672A - processos para preparar imatinib e um sal de adição ácida deste, sais de adição ácida de imatinib, composição farmaceuticamente aceitável deste, imatinib e uso deste - Google Patents

processos para preparar imatinib e um sal de adição ácida deste, sais de adição ácida de imatinib, composição farmaceuticamente aceitável deste, imatinib e uso deste

Info

Publication number
BRPI0407672A
BRPI0407672A BRPI0407672-9A BRPI0407672A BRPI0407672A BR PI0407672 A BRPI0407672 A BR PI0407672A BR PI0407672 A BRPI0407672 A BR PI0407672A BR PI0407672 A BRPI0407672 A BR PI0407672A
Authority
BR
Brazil
Prior art keywords
imatinib
acid addition
addition salt
preparing
pharmaceutically acceptable
Prior art date
Application number
BRPI0407672-9A
Other languages
English (en)
Inventor
Rajendra Narayanrao Kankan
Dharmaraj Ramachandra Rao
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of BRPI0407672A publication Critical patent/BRPI0407672A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

"PROCESSOS PARA PREPARAR IMATINIB E UM SAL DE ADIçãO áCIDA DESTE, SAIS DE ADIçãO áCIDA DE IMATINIB, COMPOSIçãO FARMACEUTICAMENTE ACEITáVEL DESTE, IMATINIB E USO DESTE". A presente invenção refere-se a um processo para preparar imatinib, quer como base livre, quer como sal de adição ácida, o qual processo compreende reagir N-(2-metil-5aminofenil-4-(3-piridil)-2-pirimidina amina da fórmula (II) com haleto de 4-(4-metil-piperazino metil)benzoíla de fórmula (III) na presença de um solvente orgânico inerte, de maneira a produzir um sal de hidrohaleto de imatinib de fórmula (I) onde n representa 1, 2 ou 3 e Hal representa bromo, cloro, flúoro ou iodo, quer na forma anidra, quer na forma hidratada que pode, conforme desejado, opcionalmente ser adicionalmente convertido quer na base livre, quer em um sal de adição ácida adicional. A presente invenção também se refere ao imatinib preparado de acordo com o processo acima.
BRPI0407672-9A 2003-02-18 2004-01-08 processos para preparar imatinib e um sal de adição ácida deste, sais de adição ácida de imatinib, composição farmaceuticamente aceitável deste, imatinib e uso deste BRPI0407672A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0303730A GB2398565A (en) 2003-02-18 2003-02-18 Imatinib preparation and salts
PCT/GB2004/000018 WO2004074502A2 (en) 2003-02-18 2004-01-08 A process of preparing imatinib

Publications (1)

Publication Number Publication Date
BRPI0407672A true BRPI0407672A (pt) 2006-03-01

Family

ID=9953245

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407672-9A BRPI0407672A (pt) 2003-02-18 2004-01-08 processos para preparar imatinib e um sal de adição ácida deste, sais de adição ácida de imatinib, composição farmaceuticamente aceitável deste, imatinib e uso deste

Country Status (12)

Country Link
US (1) US7638627B2 (pt)
EP (1) EP1599462B1 (pt)
JP (1) JP5064024B2 (pt)
KR (1) KR101086845B1 (pt)
AU (1) AU2004213616B2 (pt)
BR (1) BRPI0407672A (pt)
CA (1) CA2516370C (pt)
GB (1) GB2398565A (pt)
NZ (1) NZ542040A (pt)
PL (1) PL378128A1 (pt)
RU (1) RU2415849C2 (pt)
WO (1) WO2004074502A2 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
AU2004246800B2 (en) * 2003-06-13 2008-12-04 Novartis Ag 2-aminopyrimidine derivatives as Raf kinase inhibitors
AR047530A1 (es) * 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
WO2005077933A1 (en) * 2004-02-11 2005-08-25 Natco Pharma Limited Novel polymorphic form of imatinib mesylate and a process for its preparation
KR101348625B1 (ko) * 2004-09-02 2014-01-07 씨아이피엘에이 엘티디. 이매티닙 메실레이트의 안정한 결정형 및 그의 제조방법
MX2007003506A (es) * 2004-09-27 2007-05-10 Aztrazeneca Ab Terapia de combinacion de cancer que comprende azd2171 e imatinib.
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
CN102861338A (zh) * 2006-04-05 2013-01-09 诺瓦提斯公司 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
EP2311821A1 (en) * 2006-04-27 2011-04-20 Sicor, Inc. Polymorphic form of Imatinib mesylate and processes for its preparation
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
WO2008024830A2 (en) * 2006-08-23 2008-02-28 Board Of Regents, The University Of Texas System Radiohaloimatinibs and methods of their synthesis and use in pet imaging of cancers
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
EP2009008A1 (en) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
KR20090061055A (ko) * 2006-10-26 2009-06-15 시코르, 인크. 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법
RU2329260C1 (ru) * 2007-02-20 2008-07-20 Юрий Иосифович Копырин Способ получения 2-анилинопиримидинов или их солей (варианты)
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
PT2305263E (pt) * 2007-06-07 2012-10-22 Novartis Ag Formas amorfas estabilizadas de mesilato de imatinib
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
WO2009060463A1 (en) * 2007-11-05 2009-05-14 Natco Pharma Limited An environmentally friendly process for the preparation of imatinib base
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
WO2009080366A1 (en) * 2007-12-22 2009-07-02 Synthon B.V. A process of making imatinib
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
US20110306763A1 (en) 2009-12-10 2011-12-15 Shanghai Parling Pharmatech Co., Ltd. Process for the preparation of imatinib and salts thereof
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011114337A1 (en) * 2010-03-15 2011-09-22 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
WO2011130918A1 (zh) 2010-04-23 2011-10-27 上海百灵医药科技有限公司 一种伊马替尼的合成方法
CN103864752B (zh) * 2010-05-19 2015-11-25 江苏豪森药业股份有限公司 甲磺酸伊马替尼的晶型及其制备方法
EP2582689B1 (en) 2010-06-18 2017-03-01 KRKA, D.D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
TR201007005A2 (tr) * 2010-08-23 2011-09-21 Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. İmatinib baz üretim yöntemi
CN101899035B (zh) * 2010-09-03 2012-09-05 天津市炜杰科技有限公司 一种高纯度伊马替尼的制备方法
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US8703788B2 (en) * 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
TR201010618A2 (tr) 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
CN102070605B (zh) * 2011-01-30 2013-03-13 南京卡文迪许生物工程技术有限公司 甲磺酸伊马替尼多晶型物和药用组合物
KR101286780B1 (ko) * 2011-02-01 2013-07-17 에스티팜 주식회사 비카보네이트 염 및 이를 이용한 이마티니브 또는 이의 염의 제조방법
CN102382100B (zh) * 2011-03-09 2014-04-16 上海昕盛医药科技有限公司 伊马替尼的制备方法
JP2014509642A (ja) 2011-03-31 2014-04-21 アイエヌディー−スイフト ラボラトリーズ リミテッド イマチニブ及びそのメシル酸塩の生成のための改良方法
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CN102260242B (zh) * 2011-05-27 2014-08-06 南京卡文迪许生物工程技术有限公司 甲磺酸伊马替尼多晶型物及其药用组合物
CN102816145B (zh) * 2011-06-11 2014-09-03 南京卡文迪许生物工程技术有限公司 甲磺酸伊马替尼多晶型物及其药用组合物
WO2013035102A1 (en) 2011-09-05 2013-03-14 Natco Pharma Limited Processes for the preparation of imatinib base and intermediates thereof
EP2776035B1 (en) * 2011-11-01 2016-08-10 Modgene, Llc Compositions and methods for reduction of amyloid-beta load
CN102659762A (zh) * 2012-05-24 2012-09-12 石药集团中奇制药技术（石家庄）有限公司 一种甲磺酸伊马替尼晶型及其制备方法
WO2014041551A1 (en) 2012-09-14 2014-03-20 Natco Pharma Limited Formulation comprising imatinib as oral solution
EP2749557A1 (en) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate
CN104163812A (zh) * 2013-05-17 2014-11-26 浙江九洲药业股份有限公司 一种无定型的伊马替尼甲磺酸盐及其制备方法
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
CA2919498C (en) 2013-07-31 2023-07-25 Windward Pharma, Inc. Aerosol nintedanib compounds and uses thereof
CN103910711A (zh) * 2014-03-24 2014-07-09 福建天泉药业股份有限公司 一种伊马替尼游离碱晶型及其制备方法
CN104974133B (zh) * 2014-04-09 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种甲磺酸伊马替尼晶型及其制备方法
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
EA035891B1 (ru) 2016-01-25 2020-08-27 КРКА, д.д., НОВО МЕСТО Быстродиспергируемая фармацевтическая композиция, включающая ингибитор тирозинкиназы
US20200360277A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations of imatinib, imatinib metabolites, imatinib salts, their manufacture, and uses thereof
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
SG10201909596RA (en) * 2019-10-14 2021-05-28 Esco Aster Pte Ltd Synthesis of Tyrosine Kinase Inhibitors
CN119490479B (zh) * 2024-11-15 2025-08-12 广州科锐特药业有限公司 一种甲磺酸伊马替尼的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (pt) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR101086845B1 (ko) 2011-11-24
KR20050108358A (ko) 2005-11-16
JP2006518360A (ja) 2006-08-10
US20060173182A1 (en) 2006-08-03
JP5064024B2 (ja) 2012-10-31
WO2004074502A3 (en) 2004-10-28
PL378128A1 (pl) 2006-03-06
AU2004213616A2 (en) 2004-09-02
AU2004213616A1 (en) 2004-09-02
GB2398565A (en) 2004-08-25
EP1599462B1 (en) 2013-03-27
WO2004074502A2 (en) 2004-09-02
NZ542040A (en) 2009-02-28
AU2004213616B2 (en) 2011-05-26
EP1599462A2 (en) 2005-11-30
GB0303730D0 (en) 2003-03-26
RU2415849C2 (ru) 2011-04-10
RU2005129100A (ru) 2006-06-10
CA2516370C (en) 2012-08-21
CA2516370A1 (en) 2004-09-02
US7638627B2 (en) 2009-12-29

Similar Documents

Publication Publication Date Title
BRPI0407672A (pt) processos para preparar imatinib e um sal de adição ácida deste, sais de adição ácida de imatinib, composição farmaceuticamente aceitável deste, imatinib e uso deste
EA200400387A1 (ru) Азабициклические замещённые конденсированные гетероарильные соединения для лечения заболеваний
CR7080A (es) Sales tartrato de 5,8,14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
BR0214031A (pt) Compostos de heteroarila azabicìclico substituìdos para o tratamento de doenças
DK1781683T3 (da) Fremgangsmåde til fremstilling af 17-vinyl-triflater som halvfabrikata
PE20081530A1 (es) Nuevos compuestos 617
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
PE20060497A1 (es) Aminas policiclicas sustituidas con arilo como antagonistas de mch
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
BR0212477A (pt) 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
ATE554085T1 (de) Neue inhibitoren von glutaminylcyclase
ATE372767T1 (de) Dpp-iv-hemmer
SV2005002083A (es) Derivados de la 1-amino-ftalazina, su preparacion y aplicacion en terapeutica
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
ATE544744T1 (de) Verfahren zur herstellung von benzoesaure derivaten
BRPI0116227B8 (pt) processo para a preparação de imidazotriazinonas substituídas por sulfonamida
EA200401510A1 (ru) Способ получения производных 5-(1, 3-оксазол-2-ил)бензойной кислоты
JP2007507443A5 (pt)
SE0000933D0 (sv) Method of producing 6-substituted (S)-nicotine derivatives and intermediate compounds
DE502006002659D1 (de) Verfahren zur herstellung von 5-(4-ä4-(5-cyano-3-indolyl)-butylü-1-piperazinyl)-benzofuran-2-carboxamid
BRPI0406704A (pt) Antagonistas de 5ht~7~ e agonistas inversos
ATE449082T1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
UY27074A1 (es) Derivados de aminotriazolopiridina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: CIPLA LIMITED (IN)

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]